Linked Life Data

15106031

Source:http://linkedlifedata.com/resource/pubmed/id/15106031

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
13-14
pubmed:dateCreated
2004-4-23
pubmed:abstractText
Assessing airway inflammation is important for investigating the underlying mechanisms of many lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). Yet these are not measured directly in routine clinical practice because of the difficulties in monitoring inflammation. The presence and type of airway inflammation can be difficult to detect clinically, and may result in delays in initiating appropriate therapy. Non-invasive monitoring may assist in differential diagnosis of lung diseases, assessment of their severity and response to treatment. There is increasing evidence that breath analysis may have an important place in the diagnosis and clinical management of asthma, COPD, primary ciliary dyskinesia (PCD) and other major lung disease. The article reviews whether current noninvasive measurements of exhaled gases, such as nitric oxide (NO), hydrocarbons, inflammatory markers exhaled breath condensate (EBC) are ready for routine use in clinical practice.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1424-7860
pubmed:author
pubmed:issnType
Print
pubmed:day
3
pubmed:volume
134
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
175-92
pubmed:dateRevised
2011-2-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Exhaled markers of inflammatory lung diseases: ready for routine monitoring?
pubmed:affiliation
National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, UK. s.kharitonov@imperial.ac.uk
pubmed:publicationType
Journal Article, Review